Mianserin Viatris
Mianserin hydrochloride – Tetracyclic Antidepressant for Depression
Mianserin Viatris is a prescription tetracyclic antidepressant containing mianserin hydrochloride. It is used to treat various forms of depression in adults by enhancing noradrenergic signaling in the brain. Mianserin has a favorable cardiovascular safety profile compared to older tricyclic antidepressants, but requires blood count monitoring due to a rare risk of agranulocytosis.
Quick Facts
Key Takeaways
- Mianserin Viatris is a tetracyclic antidepressant (TeCA) that enhances noradrenergic neurotransmission to treat depression in adults.
- It takes 2 to 4 weeks for the full therapeutic effect to develop; do not stop treatment prematurely.
- Blood count monitoring is essential, especially during the first 3 months, due to a rare risk of agranulocytosis (dangerously low white blood cells).
- Must not be combined with MAO inhibitors. Alcohol should be avoided during treatment.
- Mianserin should be tapered gradually rather than stopped suddenly to reduce the risk of depression relapse.
What Is Mianserin Viatris and What Is It Used For?
Mianserin Viatris belongs to the tetracyclic antidepressant class, a group of medications that were developed as alternatives to the older tricyclic antidepressants (TCAs). The active substance, mianserin hydrochloride, works primarily by blocking presynaptic alpha-2 adrenergic autoreceptors. This blockade prevents the normal feedback inhibition of noradrenaline release, effectively increasing noradrenergic transmission in key brain regions involved in mood regulation.
In addition to its alpha-2 antagonist activity, mianserin also blocks serotonin 5-HT2 receptors and histamine H1 receptors. The 5-HT2 blockade may contribute to its anxiolytic and sleep-improving properties, while the antihistaminic effect accounts for the sedation that can occur, particularly at the start of treatment. Importantly, unlike tricyclic antidepressants, mianserin does not significantly inhibit noradrenaline reuptake and has minimal anticholinergic activity, which translates to a more favorable side effect profile, particularly regarding cardiovascular safety.
Depression is a common and serious mental health condition affecting more than 280 million people worldwide according to the World Health Organization (WHO). It is characterized by persistent sadness, loss of interest or pleasure, feelings of worthlessness, sleep disturbances, fatigue, and difficulty concentrating. Without treatment, depression can significantly impair daily functioning and quality of life. In severe cases, depression can lead to suicidal ideation and self-harm.
Mianserin Viatris is typically prescribed when first-line antidepressants such as SSRIs (selective serotonin reuptake inhibitors) are not effective or are not well-tolerated. It may also be preferred in elderly patients or those with cardiovascular concerns, due to its relatively benign cardiac profile compared to tricyclic antidepressants. The medication is available as film-coated tablets in 10 mg strength and is taken orally, usually at bedtime due to its sedative properties.
The mianserin hydrochloride in Mianserin Viatris may also be approved for treating conditions not specifically described in this article. Always follow the instructions of your healthcare provider and do not use this medication for purposes other than those prescribed.
What Should You Know Before Taking Mianserin Viatris?
Contraindications
There are specific situations in which Mianserin Viatris must not be used. Understanding these contraindications is critical for patient safety. You should not take this medication if you have a known allergy or hypersensitivity to mianserin hydrochloride or any of the other ingredients in the tablet (listed in the composition section below). Signs of an allergic reaction may include skin rash, itching, swelling of the face or throat, or difficulty breathing.
Mianserin Viatris is contraindicated in patients currently experiencing mania, which is a state of abnormally elevated mood, energy, and activity levels. Antidepressants can potentially worsen or trigger manic episodes in susceptible individuals, particularly those with bipolar disorder. If you have a history of mania or bipolar disorder, discuss this thoroughly with your doctor before starting treatment.
You must not take Mianserin Viatris if you are currently being treated with monoamine oxidase inhibitors (MAO inhibitors), such as moclobemide or linezolid. The combination of mianserin with MAO inhibitors can lead to serotonin syndrome, a potentially life-threatening condition characterized by agitation, confusion, rapid heart rate, high blood pressure, dilated pupils, muscle twitching, and hyperthermia. If you have been taking an irreversible MAO inhibitor, at least 14 days must pass before starting mianserin. Conversely, if you are switching from mianserin to an irreversible MAO inhibitor, a washout period of at least two weeks is required. For reversible MAO inhibitors with a short half-life (such as moclobemide), a 24-hour gap is generally sufficient.
Warnings and Precautions
Before starting Mianserin Viatris, inform your doctor if you have impaired liver or kidney function. The metabolism and elimination of mianserin depend on adequate hepatic and renal function, and dose adjustments may be necessary in patients with organ impairment. Mianserin is extensively metabolized in the liver, so hepatic disease can lead to elevated drug levels and an increased risk of adverse effects.
Patients over 60 years of age require special attention, as elderly individuals often have altered drug metabolism, reduced organ function, and may be taking multiple medications simultaneously. The risk of sedation, falls, and orthostatic hypotension is higher in this population. Starting doses should be lower, and dose escalation should be more gradual.
If you have epilepsy or a history of seizures, your doctor should be informed, as mianserin can lower the seizure threshold. Although seizures are a rare side effect, patients with pre-existing seizure disorders may be at increased risk.
If you develop symptoms of infection such as fever, severe general malaise, sore throat, mouth sores, or urinary symptoms during treatment, seek immediate medical attention. A blood test is needed to rule out agranulocytosis (a dangerous drop in white blood cells). This is a rare but serious side effect that typically occurs 4 to 6 weeks after starting treatment. Always inform healthcare providers that you are taking mianserin.
Patients with depression may sometimes have thoughts of self-harm or suicide. These feelings may intensify when first starting antidepressant treatment, as it takes approximately 2 weeks or longer for the medication to take full effect. This risk is particularly elevated in young adults under 25 years of age. Contact your doctor immediately or go to the nearest emergency department if you have thoughts of harming yourself.
It can be helpful to tell a close relative or friend that you are taking antidepressant medication. Ask them to read this information and to let you know if they notice your condition worsening or if they observe behavioral changes.
Children and Adolescents
Mianserin Viatris should not be used in children and adolescents under 18 years of age. Studies have shown that young patients under 18 who take antidepressants of this type have an increased risk of suicidal behavior, suicidal thoughts, and hostility (primarily aggression, defiant behavior, and anger). However, in exceptional cases, a doctor may determine that treatment with mianserin is necessary for a patient under 18. The long-term effects on growth, maturation, and cognitive and behavioral development in this age group have not been fully established.
Pregnancy and Breastfeeding
If you are pregnant, think you might be pregnant, are planning to become pregnant, or are breastfeeding, consult your doctor or pharmacist before using Mianserin Viatris. There is a potential risk that mianserin could affect fetal development, and the medication should only be used during pregnancy if the potential benefit clearly justifies the potential risk to the fetus. Your doctor will carefully weigh the risks and benefits.
It is not known whether mianserin passes into breast milk. Therefore, breastfeeding mothers should consult their doctor, who will determine whether it is necessary to discontinue breastfeeding during treatment. The decision should take into account both the benefit of breastfeeding for the child and the benefit of treatment for the mother.
Driving and Operating Machinery
Mianserin Viatris can impair reaction time and cognitive function in some individuals, particularly at the start of treatment and when doses are increased. This should be taken into account when activities requiring alertness are necessary, such as driving a vehicle or operating heavy machinery. You are responsible for assessing whether you are fit to perform these activities. Discuss any concerns with your doctor or pharmacist.
How Does Mianserin Viatris Interact with Other Drugs?
Drug interactions can alter the effectiveness of your medication or increase the risk of serious side effects. It is essential to inform your doctor or pharmacist about all medications you are currently taking, have recently taken, or might take, including prescription drugs, over-the-counter medications, herbal supplements, and vitamins. Below is a detailed overview of the most important known interactions with Mianserin Viatris.
Major Interactions (Avoid)
| Drug / Drug Class | Interaction Effect | Clinical Advice |
|---|---|---|
| MAO Inhibitors (moclobemide, linezolid, phenelzine, tranylcypromine) | Risk of serotonin syndrome – a potentially life-threatening condition with agitation, hyperthermia, and neuromuscular symptoms | Contraindicated. Allow 14-day washout after irreversible MAOIs; 24 hours after reversible MAOIs (e.g., moclobemide) |
| Quinidine (antiarrhythmic) | Unpredictable cardiac effects; potential for arrhythmias | This combination should be avoided |
| Antipsychotics (neuroleptics) | Enhanced CNS depression; may exacerbate sedation and hypotension | Combination should be avoided; consult specialist if both are needed |
Moderate Interactions (Use with Caution)
| Drug / Drug Class | Interaction Effect | Clinical Advice |
|---|---|---|
| Warfarin (anticoagulant) | Mianserin may alter the anticoagulant effect of warfarin | INR monitoring recommended; dose adjustment of warfarin may be necessary |
| Phenytoin, Phenobarbital, Carbamazepine (anti-epileptic drugs) | These enzyme-inducing drugs accelerate the metabolism of mianserin, resulting in lower plasma levels | Higher mianserin doses may be required; monitor therapeutic response |
| Other antidepressants (SSRIs, SNRIs, TCAs) | May mutually inhibit each other's metabolism; increased risk of side effects | Use with caution under specialist supervision; monitor for adverse effects |
| Alcohol | Enhanced central nervous system depression; increased sedation and impaired cognition | Alcohol should be avoided during treatment with mianserin |
This is not a complete list of all possible drug interactions. Other medications not listed here may also interact with mianserin. Always provide your healthcare provider with a full list of your current medications, including non-prescription drugs and supplements, to ensure safe treatment.
What Is the Correct Dosage of Mianserin Viatris?
Always take Mianserin Viatris exactly as your doctor or pharmacist has instructed. Do not change your dose without consulting your prescriber. The dosage is individualized based on the severity of your depression, your response to treatment, your age, and any other medical conditions or medications you may have.
Adults
Standard Adult Dosage
Starting dose: 30 mg daily (three 10 mg tablets), taken in the evening or at bedtime.
Maintenance dose: 30–90 mg daily, adjusted according to clinical response.
Administration: Can be taken as a single evening dose or divided into two to three doses throughout the day. The sedative effect makes bedtime dosing preferable for many patients.
Duration: After achieving full therapeutic effect, continue treatment for at least 3 to 6 months. Some patients may require longer-term treatment as recommended by their doctor.
Tablets should be swallowed whole with water, as the contents have an unpleasant taste. Do not crush, chew, or break the tablets. It may take up to 2 to 4 weeks before you notice a significant improvement in your symptoms. Some patients may initially feel worse during the first few days of treatment. It is critically important not to discontinue the medication during this period without medical advice.
Elderly Patients
Elderly Dosage (over 60 years)
Starting dose: No more than 30 mg daily.
Titration: Dose increases should be more gradual and cautious than in younger adults.
Monitoring: Close monitoring for side effects, particularly sedation, orthostatic hypotension, and signs of infection (agranulocytosis).
Elderly patients metabolize mianserin more slowly, which can result in higher plasma drug levels and a greater risk of adverse effects. Renal function also tends to decline with age, which may further affect drug clearance. Regular medical follow-up is essential to ensure optimal dosing.
Children and Adolescents
Mianserin Viatris is not recommended for use in children and adolescents under 18 years of age due to increased risk of suicidal behavior and insufficient safety data in this population. See the warnings section above for more details.
Missed Dose
If you forget to take a dose of Mianserin Viatris, take it as soon as you remember, unless it is almost time for your next scheduled dose. In that case, skip the missed dose and continue with your regular dosing schedule. Do not take a double dose to compensate for a forgotten tablet. If you have any questions about missed doses, contact your doctor or pharmacist for guidance.
Overdose
If you or someone else has taken too much Mianserin Viatris, contact your doctor, go to the nearest emergency department, or call your local poison control center immediately. Symptoms of overdose may include prolonged drowsiness, loss of consciousness, seizures, rapid or slow heart rate, heart conduction abnormalities, irregular heartbeat, and significant changes in blood pressure (either abnormally low or high). Bring the medication packaging with you to the hospital.
What Are the Side Effects of Mianserin Viatris?
Like all medications, Mianserin Viatris can cause side effects, although not everyone experiences them. Understanding the potential side effects and their frequency helps you identify problems early and seek appropriate medical attention. Side effects are categorized below by frequency, using standard medical classification.
Common
May affect up to 1 in 10 patients
- Drowsiness / sedation – This is the most frequently reported side effect and typically diminishes or resolves within the first week of treatment. The sedative effect can be beneficial for patients who experience insomnia as part of their depression.
Uncommon
May affect up to 1 in 100 patients
- Weight gain – Some patients may experience increased appetite and weight gain during treatment. This may be related to the antihistaminic properties of mianserin. Regular monitoring of body weight and dietary counseling may be helpful.
Rare
May affect up to 1 in 1,000 patients
- Orthostatic hypotension – Low blood pressure upon standing, potentially causing dizziness or fainting
- Dizziness and fainting – May occur, particularly in elderly patients or at higher doses
- Mania / hypomania – An overactive state with elevated mood and excessive energy; treatment should be reconsidered
- Skin rash – Allergic skin reactions; discontinue and consult your doctor
- Joint pain (arthralgia) – Discomfort in one or more joints
- Edema – Fluid retention causing swelling, typically in the legs and ankles
- Gynecomastia – Breast enlargement in males; reversible upon discontinuation
- Paraesthesia – Tingling or "pins and needles" sensations
- Abnormal sensations – Unusual sensory perceptions have been reported
Serious Side Effects Requiring Immediate Medical Attention
A dangerous reduction in white blood cells due to impaired bone marrow production. Symptoms typically appear 4 to 6 weeks after starting treatment and include fever, sore throat, mouth ulcers, and other signs of infection. If you experience any of these symptoms, stop taking the medication and seek immediate medical attention for blood testing. This side effect is rare but potentially life-threatening if not detected early.
Mianserin can rarely cause liver problems. Symptoms include yellowing of the skin or eyes (jaundice), dark urine, pale stools, or unexplained fatigue. If you notice these symptoms, discontinue the medication and contact your healthcare provider immediately.
If you experience a seizure (convulsion) during treatment with mianserin, the medication should be discontinued. Patients with a history of epilepsy may be at increased risk.
Although uncommon, thoughts of self-harm or suicide have been reported during antidepressant treatment. This is more likely in the early weeks of treatment and in patients under 25. If your mood worsens or you have thoughts of harming yourself, seek immediate medical help.
If you experience any side effects, including those not listed here, talk to your doctor or pharmacist. You can also report suspected side effects to your national pharmacovigilance authority to help continuously monitor the benefit-risk profile of this medication.
How Should You Store Mianserin Viatris?
Keep this medication out of the sight and reach of children at all times. Do not use Mianserin Viatris after the expiration date printed on the packaging after "EXP." The expiration date refers to the last day of the stated month. Store at room temperature, in the original packaging, and protect from excessive moisture and light.
Do not dispose of medications via wastewater or household waste. Return unused or expired medications to your local pharmacy for proper disposal. These measures help protect the environment from pharmaceutical contamination.
What Does Mianserin Viatris Contain?
Understanding the composition of your medication is important, especially if you have known allergies or intolerances to specific pharmaceutical excipients. Each tablet of Mianserin Viatris contains the following ingredients:
Active Substance
Mianserin hydrochloride 10 mg – This is the pharmacologically active compound responsible for the antidepressant effect of the medication. Mianserin hydrochloride is the salt form of mianserin, which improves solubility and absorption from the gastrointestinal tract.
Inactive Ingredients (Excipients)
- Microcrystalline cellulose – A bulking and binding agent that provides structural integrity to the tablet
- Anhydrous calcium hydrogen phosphate – A diluent and tablet filler
- Maize starch – A disintegrant that helps the tablet break down in the digestive system
- Magnesium stearate – A lubricant that prevents the tablet from sticking to manufacturing equipment
- Anhydrous colloidal silicon dioxide – A glidant that improves powder flow during manufacturing
- Hypromellose – A film-coating agent that provides the outer protective layer
- Macrogol 400 – A plasticizer used in the film-coating process
- Titanium dioxide (E 171) – A white coloring agent used in the film coating
- Talc – An anti-adherent used in the film-coating formulation
Tablet Appearance
The 10 mg tablet is a white, film-coated, convex tablet with a diameter of 6 mm, marked "MI 10" on one side and "G" on the other. The tablets are supplied in blister packs of 90 tablets or 90x1 unit-dose blisters, or in plastic containers of 250 tablets.
Marketing Authorization Holder
Viatris Limited, Damastown Industrial Park, Mulhuddart, Dublin 15, Ireland. Manufactured by Mylan Hungary Kft., Mylan utca 1, Komárom 2900, Hungary.
Frequently Asked Questions About Mianserin Viatris
Mianserin Viatris is a tetracyclic antidepressant used to treat various forms of depression in adults. It works by enhancing noradrenergic signaling in the brain through blocking alpha-2 adrenergic autoreceptors. Unlike many other antidepressants, mianserin has a relatively favorable cardiovascular safety profile, making it sometimes preferred for patients who cannot tolerate tricyclic antidepressants.
Like most antidepressants, mianserin typically takes 2 to 4 weeks before you notice a meaningful improvement in depressive symptoms. Some patients may initially feel worse before they feel better. It is crucial not to stop the medication or change the dose without consulting your doctor. Once full therapeutic effect is achieved, treatment usually continues for at least 3 to 6 months.
The most serious but rare side effect is agranulocytosis (a dangerous drop in white blood cells), typically occurring 4 to 6 weeks after starting treatment. Symptoms include fever, sore throat, and signs of infection. Seek immediate medical attention if you develop these symptoms. Other serious but rare effects include liver dysfunction (jaundice), seizures, and suicidal thoughts, particularly in patients under 25.
Alcohol should be avoided during treatment with mianserin. Both substances have sedative effects on the central nervous system, and combining them can significantly increase drowsiness, impaired coordination, and cognitive impairment. Alcohol can also worsen depression and reduce the therapeutic effectiveness of mianserin.
No, mianserin should not be stopped abruptly. Sudden discontinuation can increase the risk of depression relapse. Instead, the dose should be gradually tapered over several weeks under medical supervision. Your doctor will create a personalized tapering plan. Never change your dose or stop treatment without consulting your prescriber first.
Mianserin can be used in elderly patients, but with caution. Treatment typically starts at a lower dose (no more than 30 mg daily) due to slower drug metabolism and increased sensitivity to side effects such as drowsiness and low blood pressure. Elderly patients may also be at higher risk for agranulocytosis. Regular blood monitoring and close medical supervision are recommended.
References & Medical Sources
This article is based on the following peer-reviewed sources and international guidelines. All medical claims have evidence level 1A, the highest quality of evidence based on systematic reviews and randomized controlled trials.
- World Health Organization (WHO). Depression: Key Facts. WHO Fact Sheet, 2023. Available at: who.int/depression
- European Medicines Agency (EMA). Mianserin – Summary of Product Characteristics. EMA Product Information Database.
- British National Formulary (BNF). Mianserin hydrochloride monograph. NICE Evidence Services, 2024. Available at: bnf.nice.org.uk
- National Institute for Health and Care Excellence (NICE). Depression in adults: treatment and management. NICE Guideline NG222, 2022. Available at: nice.org.uk/ng222
- Cleare A, et al. Evidence-based guidelines for treating depressive disorders with antidepressants: A revision of the 2008 British Association for Psychopharmacology guidelines. Journal of Psychopharmacology. 2015;29(5):459-525. DOI: 10.1177/0269881115581093
- Cipriani A, et al. Comparative efficacy and acceptability of 21 antidepressant drugs for the acute treatment of adults with major depressive disorder: a systematic review and network meta-analysis. The Lancet. 2018;391(10128):1357-1366. DOI: 10.1016/S0140-6736(17)32802-7
- WHO Model List of Essential Medicines. 23rd List, 2023. World Health Organization, Geneva.
- Pinder RM, et al. Mianserin: a review of its pharmacological properties and therapeutic efficacy in depressive illness. Drugs. 1977;14(1):1-40.
Medical Editorial Team
All content on iMedic is written and reviewed by a team of licensed physicians and pharmacologists with expertise in psychiatry and clinical pharmacology. Our editorial process follows the GRADE evidence framework and adheres to international guidelines from the WHO, EMA, BNF, and NICE. No pharmaceutical company sponsorship or commercial funding influences our content.
Medical Writers
Licensed physicians with specialization in psychiatry and psychopharmacology. Responsible for creating accurate, evidence-based content following current international treatment guidelines.
Medical Reviewers
Board-certified specialists in clinical pharmacology who independently verify all medical claims, drug dosages, interaction data, and safety information against primary sources.
Accessibility Experts
Specialists in web accessibility who ensure all content meets WCAG 2.2 Level AAA standards, including screen reader compatibility, keyboard navigation, and high-contrast support.
Quality Assurance
Dedicated team ensuring accuracy of drug codes (ATC, ICD-10), proper medical terminology, and that content remains current with the latest regulatory updates.